Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Off-label Use of Oral Immunotherapy for Rhinoconjunctivitis and Asthma due to Grass Pollen: A Safe and Effective Alternative in Patients over 65 Years Old: A Series of Case Reports

Author(s): Lucía González-Bravo, Jimena Laiseca García, Martina Privitera and Ana Rosado*

Volume 18, Issue 4, 2023

Published on: 03 November, 2022

Page: [599 - 602] Pages: 4

DOI: 10.2174/1574886317666221010092132

Price: $65

Abstract

Introduction: Allergic rhinoconjunctivitis and asthma are the most common IgE-mediated diseases worldwide. Allergen-specific immunotherapy (AIT) is currently the only modifying treatment for these IgE-mediated diseases in both children and adults. Subcutaneous immunotherapy is widely used, but in patients over 65 years old, there may be an increased risk of adverse reactions and a worse response to treatment. Oral immunotherapy (OIT) has been proven to be effective and safe, but currently, in most countries, it has been licensed only for patients up to 65 years old based on its technical datasheet. So far, no studies on the efficacy and safety of this type of immunotherapy in patients older than 65 years old have been published.

Case Presentation: We present four patients older than 65 years old with a diagnosis of moderate seasonal rhinoconjunctivitis and moderate-persistent seasonal pollen-induced asthma. Off-label use of oral immunotherapy (OIT) for grass pollen was prescribed due to the severity of their rhinoconjunctivitis symptoms and the worsening of asthma symptoms during the spring. Improvement in the rhinoconjunctivitis and asthma symptoms was reported by all patients since the first spring season and was maintained during the following two years of follow-up. There were no systemic reactions, and only two patients initially had self-limiting oral pruritus.

Conclusion: Oral immunotherapy for pollens appears to be a convenient, effective, and safe option in older patients (>65 years) with comorbidities after a three-year treatment. This is, to the best of our knowledge, the first report on the off-label use of OIT in patients over 65 years old with symptoms of allergic rhinoconjunctivitis and asthma.

« Previous Next »
[1]
Calderon MA, Penagos M, Sheikh A, Canonica GW, Durham SR. Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta-analysis. Clin Exp Allergy 2011; 41(9): 1263-72.
[http://dx.doi.org/10.1111/j.1365-2222.2011.03835.x] [PMID: 21848759]
[2]
Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World allergy organization position paper 2013 update. World Allergy Organ J 2014; 7(1): 6.
[http://dx.doi.org/10.1186/1939-4551-7-6] [PMID: 24679069]
[3]
Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: American academy of allergy, asthma & immunology/european academy of allergy and clinical immunology/PRACTALL consensus report. J Allergy Clin Immunol 2013; 131(5): 1288-96.
[http://dx.doi.org/10.1016/j.jaci.2013.01.049] [PMID: 23498595]
[4]
Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: The world allergy organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol 2010; 125(3): 569-574.e7.
[http://dx.doi.org/10.1016/j.jaci.2009.10.060] [PMID: 20144472]
[5]
Cox LS, Linnemann DL, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: A comprehensive review. J Allergy Clin Immunol 2006; 117(5): 1021-35.
[http://dx.doi.org/10.1016/j.jaci.2006.02.040] [PMID: 16675328]
[6]
Didier A, Wahn U, Horak F, Cox LS. Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience. Expert Rev Clin Immunol 2014; 10(10): 1309-24.
[http://dx.doi.org/10.1586/1744666X.2014.957677] [PMID: 25205329]
[7]
Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2020. Available from: http://ginasthma.org/ (Accessed on: January 2021).
[8]
Casale TB, Cox LS, Wahn U, Golden DBK, Bons B, Didier A. Safety review of 5-grass pollen tablet from pooled data of clinical trials. J Allergy Clin Immunol Pract 2017; 5(6): 1717-27.
[http://dx.doi.org/10.1016/j.jaip.2017.04.020] [PMID: 28734858]
[9]
Dahl R, Kapp A, Colombo G, et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008; 121(2): 512-8.
[http://dx.doi.org/10.1016/j.jaci.2007.10.039] [PMID: 18155284]
[10]
Nakonechna A, Hills J, Moor J, Dore P, Abuzakouk M. Grazax sublingual immunotherapy in pre–co-seasonal and continuous treatment regimens: Is there a difference in clinical efficacy? Ann Allergy Asthma Immunol 2015; 114(1): 73-4.
[http://dx.doi.org/10.1016/j.anai.2014.10.013] [PMID: 25457868]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy